GSK Builds Biopharmaceutical Manufacturing Facility in the U.K.

GlaxoSmithKline (GSK) has confirmed plans, originally outlined in 2010, to invest more than £500 million ($799 million) in R&D and manufacturing in the U.K. GSK will invest £350 million of the total to build a biopharmaceutical manufacturing facility at the company’s Ulverston site. It will be the first new manufacturing plant to be built by GSK in the U.K. for 40 years. The company will also spend £100 million of the total at its existing manufacturing operations at Montrose and Irvine. GSK will invest the remaining £50 million in early-stage...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers